Literature DB >> 25099175

Myc and AP-1 expression in T cells and T-cell activation in patients after hematopoietic stem cell transplantation.

Shivtia Trop-Steinberg1, Yehudith Azar, Rachel Bringer, Reuven Or.   

Abstract

Regeneration of the immune system after hematopoietic stem cell transplantation (HSCT) is a slow process. We attempted to identify problems in the recovery of the immune system by examining expressions of early event cell cycle proteins Myc, Jun, and Fos, as well as DNA binding of Myc, activating protein 1 (AP-1), and CD4 cell activation values, in phytohemagglutinin-activated T lymphocytes taken from patients after HSCT. HSCT patients showed lower protein expression levels of Myc and Jun, as well as Myc and AP-1 DNA-binding levels, as compared to healthy controls. C-Jun was lower in long-term survivors of HSCT than short-term survivors. Adenosine triphosphate (ATP) values in CD4 cells were also lower in HSCT patients than healthy controls, but showed a time-dependent increase post-transplant. Non-surviving patients showed lower levels of both Fos protein and ATP as compared to surviving patients and a negative correlation between Fos values and lymphocyte percentage that was not present in surviving patients. There was a strong positive correlation between Fos values and lymphocyte percentage and between AP-1 values and white blood count, in patients without graft-versus-host disease (GVHD), that did not exist in patients who suffered from GVHD. Patients 2 years post-HSCT showed a positive correlation between AP-1 and Myc DNA-binding protein values, similar to those values found in healthy controls. Our study identified significant factors that account for the delay in immune reconstitution after transplant; this knowledge may improve the management of post-HSCT patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25099175     DOI: 10.1007/s10238-014-0285-6

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   3.984


  53 in total

Review 1.  Transcriptional control of T-cell development.

Authors:  Taku Naito; Hirokazu Tanaka; Yoshinori Naoe; Ichiro Taniuchi
Journal:  Int Immunol       Date:  2011-09-23       Impact factor: 4.823

2.  The role of the accessory cell in mitogen-stimulated human T cell gene expression.

Authors:  J A Kern; J C Reed; R P Daniele; P C Nowell
Journal:  J Immunol       Date:  1986-08-01       Impact factor: 5.422

3.  Alterations in transcription factor binding at the IL-2 promoter region in anergized human CD4+ T lymphocytes.

Authors:  O Heisel; P Keown
Journal:  Transplantation       Date:  2001-10-27       Impact factor: 4.939

Review 4.  Cancer genetics and genomics of human FOX family genes.

Authors:  Masuko Katoh; Maki Igarashi; Hirokazu Fukuda; Hitoshi Nakagama; Masaru Katoh
Journal:  Cancer Lett       Date:  2012-09-27       Impact factor: 8.679

5.  Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay.

Authors:  Richard J Kowalski; Diane R Post; Roslyn B Mannon; Anthony Sebastian; Harlan I Wright; Gary Sigle; James Burdick; Kareem Abu Elmagd; Adriana Zeevi; Mayra Lopez-Cepero; John A Daller; H Albin Gritsch; Elaine F Reed; Johann Jonsson; Douglas Hawkins; Judith A Britz
Journal:  Transplantation       Date:  2006-09-15       Impact factor: 4.939

6.  Quantitative and qualitative signals determine T-cell cycle entry and progression.

Authors:  J F Modiano; J Mayor; C Ball; C G Chitko-McKown; N Sakata; J Domenico-Hahn; J J Lucas; E W Gelfand
Journal:  Cell Immunol       Date:  1999-10-10       Impact factor: 4.868

7.  Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management.

Authors:  Richard Kowalski; Diane Post; Mary C Schneider; Judith Britz; Judy Thomas; Mark Deierhoi; Andrew Lobashevsky; Robert Redfield; Eugene Schweitzer; Alonso Heredia; Elise Reardon; Charles Davis; Carol Bentlejewski; John Fung; Ron Shapiro; Adriana Zeevi
Journal:  Clin Transplant       Date:  2003-04       Impact factor: 2.863

8.  The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation.

Authors:  Ruoning Wang; Christopher P Dillon; Lewis Zhichang Shi; Sandra Milasta; Robert Carter; David Finkelstein; Laura L McCormick; Patrick Fitzgerald; Hongbo Chi; Joshua Munger; Douglas R Green
Journal:  Immunity       Date:  2011-12-23       Impact factor: 31.745

9.  Costimulation of peripheral blood T cell activation by human endothelial cells. Enhanced IL-2 transcription correlates with increased c-fos synthesis and increased Fos content of AP-1.

Authors:  C C Hughes; J S Pober
Journal:  J Immunol       Date:  1993-04-15       Impact factor: 5.422

Review 10.  Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.

Authors:  Søren Lykke Petersen
Journal:  Dan Med Bull       Date:  2007-05
View more
  3 in total

1.  Cereblon harnesses Myc-dependent bioenergetics and activity of CD8+ T lymphocytes.

Authors:  Rebecca S Hesterberg; Matthew S Beatty; Ying Han; Mario R Fernandez; Afua A Akuffo; William E Goodheart; Chunying Yang; Shiun Chang; Christelle M Colin; Aileen Y Alontaga; Jessica M McDaniel; Adam W Mailloux; Julia M R Billington; Lanzhu Yue; Shonagh Russell; Robert J Gillies; Sang Y Yun; Muhammad Ayaz; Nicholas J Lawrence; Harshani R Lawrence; Xue-Zhong Yu; Jianing Fu; Lancia N Darville; John M Koomen; Xiubao Ren; Jane Messina; Kun Jiang; Timothy J Garrett; Anjali M Rajadhyaksha; John L Cleveland; Pearlie K Epling-Burnette
Journal:  Blood       Date:  2020-08-13       Impact factor: 25.476

Review 2.  The Roles of IRF-8 in Regulating IL-9-Mediated Immunologic Mechanisms in the Development of DLBCL: A State-of-the-Art Literature Review.

Authors:  Mingyue Cai; Na Chen
Journal:  Front Oncol       Date:  2022-02-08       Impact factor: 6.244

Review 3.  The contribution of the intestinal microbiome to immune recovery after HCT.

Authors:  Alex E Wolfe; Kate A Markey
Journal:  Front Immunol       Date:  2022-08-18       Impact factor: 8.786

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.